Hepatocellular Carcinoma
Conditions
Interventions
Case series (continuous hepatic artery infusion of oxaliplatin combined with retitrexide):None
Sponsors
the third affiliated hospital of Sun Yat-sen university
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1)patients after liver transplantation;2)Histopathology confirmed Hepatocellular Carcinoma;3)Include at least one target lesion that can be accurately measured in size and enhanced area on dynamic contrast-enhanced CT or MRI;4)the patient's should be between the ages of 18-75 years of bone;5)BCLC stage B/C;6)ECOG-PS <2;7)Child-Pugh <7;8)the estimated survival time is more than 2 months.
Exclusion criteria
Exclusion criteria: 1)Hematological indicators: WBC 2.3, or PT >6 seconds;3)Liver function indexes: ALB 51.3 umol/L; ALT and AST > 5 times the upper limit of normal;4)Renal function index: CRE > 1.5 times the upper limit of normal value;5)Severe hypertensive disease (BP>160/100 mmHg);6)Uncontrolled ascites, hepatic encephalopathy and bleeding from esophagogastric varices;7)Severe heart, brain, kidney disease;8)Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS, Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, overall survival;ORR, Objective response rate;DCR, Disease control rate;Down-stage rate; | — |
Countries
China
Contacts
Public ContactLee Kevin
the third affiliated hospital of sun-yat sen university
Outcome results
None listed